

PRODUCT INFORMATION



L-798,106

Item No. 11129

CAS Registry No.: 244101-02-8
Formal Name: (2E)-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide

Synonyms: CM 9, GW 671021

MF: C₂₇H₂₂BrNO₄S

FW: 536.4


Purity: ≥95%

UV/Vis.: λ_{max}: 221, 285 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

L-798,106 is supplied as a crystalline solid. A stock solution may be made by dissolving the L-798,106 in the solvent of choice. L-798,106 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of L-798,106 in these solvents is approximately 10 and 20 mg/ml, respectively.

L-798,106 is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

Prostaglandin E₂ (Item No. 14010) exerts its effects through four separate G protein-coupled receptors (EP₁, EP₂, EP₃, and EP₄).¹ L-798,106 is a highly selective EP₃ receptor antagonist with K_i values of 0.3, 916, >5,000, and >5,000 nM at EP₃, EP₄, EP₁, and EP₂, respectively.² At 0.2 μM, it blocks the EP₃ agonist activity of sulprostone (Item No. 14765) on guinea pig vas deferens and trachea.³

References

1. Coleman, R.A., Smith, W.L., and Narumiya, S. Classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. *Pharmacol. Rev.* **46**, 205-229 (1994).
2. Juteau, H., Gareau, Y., Labelle, M., et al. Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP₃ prostanoid receptor. *Bioorg. Med. Chem.* **9**, 1977-1984 (2001).
3. Jones, R.L., Giembycz, M.A., and Woodward, D.F. Prostanoid receptor antagonists: Development strategies and therapeutic applications. *Br. J. Pharmacol.* **158**(1), 104-145 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM